Product Information
CLORAZEPATE 3.75 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.5241 per EA under NDC 70954015930. Its NADAC has been published 152 times since Nov 8, 2023.
FDA first approved this application on Jun 16, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3.75 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954015930
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLORAZEPATE DIPOTASSIUMApproval Type
Generic (ANDA)
FDA Application
ANDA213730FDA Approved
6/16/2022
TE Code
AB
On Market Since
6/16/2022
Pharmacological Classes
Price Statistics
The NADAC for CLORAZEPATE 3.75 MG TABLET has been published 152 times since Nov 8, 2023, and over the history we have for it it has declined 25.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5241 per EA |
|---|---|
| All-time high | $1.0264 (Nov 13, 2024) |
| All-time low | $0.5241 (Sep 23, 2026) |
| 52-week high | $0.8878 |
| 52-week low | $0.5241 |
| Median price | $0.7712 |
| Average price | $0.7579 |
| Largest weekly change | +48.9% (Sep 18, 2024) |
| Weeks tracked | 152 |
| Tracking since | Nov 8, 2023 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clorazepate Dipotassium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLORAZEPATE 3.75 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CLORAZEPATE 3.75 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.5241 per EA (NDC 70954015930), effective Sep 30, 2026.
How has the price of CLORAZEPATE 3.75 MG TABLET changed over time?
Over the history we have for it, the NADAC for CLORAZEPATE 3.75 MG TABLET has declined 25.3%. It has been tracked across 152 weekly CMS publications since Nov 8, 2023.
What are the highest and lowest recorded NADAC prices for CLORAZEPATE 3.75 MG TABLET?
Since Nov 8, 2023, the NADAC for CLORAZEPATE 3.75 MG TABLET has ranged from a low of $0.5241 (Sep 23, 2026) to a high of $1.0264 (Nov 13, 2024), with a median of $0.7712 per EA.
Are there cheaper alternatives to CLORAZEPATE 3.75 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLORAZEPATE 3.75 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CLORAZEPATE 3.75 MG TABLET?
CLORAZEPATE 3.75 MG TABLET (NDC 70954015930) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.